The mainstay of systemic FD-related therapy is ERT (recombinant α-GAL A) to replace deficient α-GAL A. Current recommendations are that in adult males with classical variants and enzyme activity < 5%, FD therapy is to be considered at diagnosis. The gene discussed is ELF3; the disease is Fabry disease.